Zobrazeno 1 - 10
of 41
pro vyhledávání: '"35"'
Autor:
Giuseppe Longo, M. Bevini, Emilio Iannitto, Luca Baldini, Carla Pieresca, P. Avanzini, Massimo Federico, Vera Clò, A.U. Di Prisco, Vittorio Silingardi, M. Brugiatelli
Publikováno v:
European Journal of Cancer. 31:1763-1767
Between January 1988 and June 1992, 35 patients with primary anaplastic large cell lymphoma (ALCL)CD30+ were referred to one of the institutions participating in GISL (Gruppo Italiano per lo Studio dei Linformi). 16 patients were treated with ProMACE
Autor:
Andrés Cervantes, Aitana Calvo, Ronan Fougeray, Josep Tabernero, Antoine Hollebecque, Thierry André, Guillem Argiles, Catherine Leger, Nadia Amellal, Laetitia Dahan
Publikováno v:
European Journal of Cancer. 112:12-19
Background and objectives Pre-clinical data have shown that combining trifluridine/tipiracil with oxaliplatin enhances anti-tumour activity compared with either monotherapy. A phase I dose-escalation study was conducted to determine the maximum toler
Autor:
Sergio Marchini, Gian Antonio Da Prada, Paolo Pedrazzoli, Vittoria Fotia, Francesco Moccia, Matteo G. Della Porta, Maurizio D'Incalci, Alberto Zambelli, Elisa Bonetti, Alberto Riccardi, Luca Beltrame, Vittorio Rosti, Richard Tancredi, Camillo Porta, Valentina Poletto, Giulia Gallizzi
Publikováno v:
European Journal of Cancer. 77:155-164
Background Neovascularisation supports the metastatic switch in many aggressive solid cancers. Tumour neovessels are mostly lined by endothelial cells sprouting from nearby capillaries, but they could also be contributed by circulating endothelial pr
Autor:
Kohei Shitara, Akihiro Sato, Toshihiko Doi, Tomohiro Nishina, Kei Muro, Shunji Takahashi, Atsushi Ohtsu, Shogo Nomura, Hideaki Bando, Kensei Yamaguchi, Hirofumi Kuno, Hirofumi Yasui
Publikováno v:
European Journal of Cancer. 62:46-53
Aim American phase I studies have reported that the recommended dose of TAS-102 (trifluridine/tipiracil) was 25 mg/m 2 twice a day (b.i.d.), although this schedule did not provide clinically relevant improvements in a phase II study of advanced gastr
Autor:
Davies, A. H. G., Larsson, G., Ardill, J., Friend, E., Jones, L., Falconi, Massimo, Bettini, Rossella, Koller, M., Sezer, O., Fleissner, C., Taal, B., Blazeby, J. M., Ramage, J. K., Quality of Life Group, E. O. R. T. C.
Publikováno v:
European Journal of Cancer. 42:477-484
Quality of life (QoL) measurements are increasingly being used as an end point in cancer clinical trials. Standard generic QoL questionnaires may not assess symptoms produced by neuroendocrine tumours. Here we report the development of a disease-spec
Autor:
Shigehiro Yagishita, Kageaki Watanabe, Satoshi Oizumi, Takamasa Hotta, Ryo Ko, Hajime Asahina, Yoshiro Nakahara, Hidenori Mizugaki, Sho Saeki, Toshiyuki Harada, Akinobu Hamada, Yuka Fujita, Taichi Takashina, Fumie Hosoda, Hiromi Nakamura, Hiroyuki Minemura, Keiichi Nakamura
Publikováno v:
European Journal of Cancer. 160:227-234
Purpose An increasing number of advanced non–small cell lung cancer (NSCLC) cases are being reported in the ageing population. However, studies on the use of afatinib in elderly patients are scarce. We conducted a prospective multicentre, single-ar
Autor:
Leontien C. M. Kremer, Eugene Suh, Bradley Benson, Gregory J. Aune, Monica Muraca, Edit Bardi, Daniel A. Mulrooney, Roderick Skinner, Gill Levitt, Liane Lockwood, Chris Plummer, Renée L. Mulder, Louis S. Constine, W. Hamish B. Wallace, Eva Frey, Christina Schindera, Ming H. Chen, Melissa M. Hudson, Emily S. Tonorezos, Elvira C. van Dalen, Ulrike Hennewig, Helena J H van der Pal, Jutta Bergler-Klein, Ulla Martinsson, Katrin Scheinemann, Matthew J. Ehrhardt
Publikováno v:
European Journal of Cancer. 156:127-137
Background Coronary artery disease (CAD) is a concerning late outcome for cancer survivors. However, uniform surveillance guidelines are lacking. Aim To harmonise international recommendations for CAD surveillance for survivors of childhood, adolesce
Autor:
M. Faehling, Frank Heinzelmann, Rainer Sätzler, Susanne Martina Eschmann, Jörn Sträter, Sabine Fallscheer, Sebastian Kramberg
Publikováno v:
European Journal of Cancer. 156:175-186
Background Recent phase II–III trials of immuno(chemo)therapy before resection in locally advanced resectable non-small cell lung cancer (NSCLC) report high rates of pathological response and promising survival. However, primarily, patients who did
Autor:
Jean-Christophe Sabourin, T. de Baere, T. Aparicio, Emmanuel Mitry, Eric Baudin, Ph. Rougier, Michel Ducreux, Martin Schlumberger
Publikováno v:
European Journal of Cancer. 37:1014-1019
A few studies have suggested an antitumour activity of somatostatin analogues in neuroendocrine tumours (NET). The aim of this study was to evaluate the antitumour efficacy of somatostatin analogues in patients with documented progressive tumours. 35
Autor:
C. Blank, Karijn P M Suijkerbuijk, Karlijn de Joode, Adriana Hepner, Céleste Lebbé, Yanina J L Jansen, Elisabeth G.E. de Vries, Andrew Haydon, Claudia Trojaniello, Lucy Storey, Paul Lorigan, Lauren Julia Brown, Alexander M. Menzies, Joanna Mangana, Astrid Aplonia Maria Van Der Veldt, Shahneen Sandhu, Bart Neyns, Douglas B. Johnson, Ellen Kapiteijn, Lisa Zimmer, Matteo S. Carlino, Georgina V. Long, Alison Weppler, Anne M. Hendriks, Harm van Tinteren, Judith M. Versluis, Mathilde Jalving, Victoria Atkinson, Prachi Bhave, Paolo A. Ascierto, Clara Allayous
Publikováno v:
European Journal of Cancer, 151, 72-83. Elsevier Ltd.
European Journal of Cancer, 151, 72-83. ELSEVIER SCI LTD
Versluis, J M, Hendriks, A M, Weppler, A M, Brown, L J, de Joode, K, Suijkerbuijk, K P M, Zimmer, L, Kapiteijn, E W, Allayous, C, Johnson, D B, Hepner, A, Mangana, J, Bhave, P, Jansen, Y J L, Trojaniello, C, Atkinson, V, Storey, L, Lorigan, P, Ascierto, P A, Neyns, B, Haydon, A, Menzies, A M, Long, G V, Lebbe, C, van der Veldt, A A M, Carlino, M S, Sandhu, S, van Tinteren, H, de Vries, E G E, Blank, C U & Jalving, M 2021, ' The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis ', European Journal of Cancer, vol. 151, pp. 72-83 . https://doi.org/10.1016/j.ejca.2021.04.003
European Journal of Cancer, 151, 72-83. ELSEVIER
European Journal of Cancer, 151, 72-83. ELSEVIER SCI LTD
Versluis, J M, Hendriks, A M, Weppler, A M, Brown, L J, de Joode, K, Suijkerbuijk, K P M, Zimmer, L, Kapiteijn, E W, Allayous, C, Johnson, D B, Hepner, A, Mangana, J, Bhave, P, Jansen, Y J L, Trojaniello, C, Atkinson, V, Storey, L, Lorigan, P, Ascierto, P A, Neyns, B, Haydon, A, Menzies, A M, Long, G V, Lebbe, C, van der Veldt, A A M, Carlino, M S, Sandhu, S, van Tinteren, H, de Vries, E G E, Blank, C U & Jalving, M 2021, ' The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis ', European Journal of Cancer, vol. 151, pp. 72-83 . https://doi.org/10.1016/j.ejca.2021.04.003
European Journal of Cancer, 151, 72-83. ELSEVIER
Introduction: In patients with metastatic melanoma, progression of a single tumour lesion (solitary progression) after response to immune checkpoint inhibition (ICI) is increasingly treated with local therapy. We evaluated the role of local therapy f